How to buy Sinovac Biotech Ltd (SVA) shares in Australia

Learn how to easily invest in Sinovac Biotech Ltd shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

Sinovac Biotech Ltd is a biotechnology business with stocks listed in the US. Sinovac Biotech Ltd shares (SVA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$6.47 – the same closing value as a week prior. Here's how to invest if you're based in Australia.

How to buy shares in Sinovac Biotech Ltd

  1. Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sinovac Biotech Ltd. Find the share by name or ticker symbol: SVA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sinovac Biotech Ltd reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of US$6.47, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Sinovac Biotech Ltd, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sinovac Biotech Ltd. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sinovac Biotech Ltd stock price (NASDAQ:SVA)

Use our graph to track the performance of SVA stocks over time.

Sinovac Biotech Ltd shares at a glance

Information last updated 2022-01-10.
52-week rangeUS$6.47 - US$6.47
50-day moving average US$6.47
200-day moving average US$6.47
Target priceUS$6
PE ratio 6.6632
Dividend yield N/A (0%)
Earnings per share (TTM) US$0.971

Where to buy Sinovac Biotech Ltd stock

Name Product Standard brokerage for US shares Currency conversion fee Markets
eToro (global stocks)
50 pips (US$0.50 for every AU$100 exchanged)
Global shares, US shares, ETFs
Zero brokerage share trading on US, Hong Kong and European stocks with trades as low as $50.
Note: This broker offers CFDs which are volatile investment products and most clients lose money trading CFDs with this provider.
Join the world’s biggest social trading network when you trade stocks, commodities and currencies from the one account.
IG Share Trading
ASX shares, Global shares
$0 brokerage for US and global shares plus get an active trader discount of $5 commission on Australian shares.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Superhero share trading
50 pips (US$0.50 for every AU$100 exchanged)
ASX shares, US shares, ETFs
Earn up to 15,000 Qantas frequent flyer points when you transfer an exisiting balance or trade. Offer valid for all new and existing Superhero members until 28 February.
Pay zero brokerage on US stocks and all ETFs and just $5 (flat fee) to trade Australian shares from your mobile or desktop.
Saxo Capital Markets (Classic account)
ASX shares, Global shares, ETFs
Access 19,000+ stocks on 40+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
SelfWealth (Basic account)
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.

Compare up to 4 providers

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.

Is it a good time to buy Sinovac Biotech Ltd stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Sinovac Biotech Ltd share growth calculator


Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.

Sinovac Biotech Ltd price performance over time

Historical closes compared with the last close of $6.47

1 week (2022-01-06) 6.47
1 month (2021-12-16) 6.47
3 months (2021-10-15) 6.47
6 months (2021-07-16) 6.47
3 years (2019-01-16) 0.31%
5 years (2017-01-13) 7.65%

Is Sinovac Biotech Ltd under- or over-valued?

Valuing Sinovac Biotech Ltd stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Sinovac Biotech Ltd's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Sinovac Biotech Ltd's P/E ratio

Sinovac Biotech Ltd's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Sinovac Biotech Ltd shares trade at around 7x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Sinovac Biotech Ltd's EBITDA

Sinovac Biotech Ltd's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$219.5 million (£0.0 million).

The EBITDA is a measure of a Sinovac Biotech Ltd's overall financial performance and is widely used to measure a its profitability.

Sinovac Biotech Ltd financials

Revenue TTM US$510.6 million
Operating margin TTM 42.26%
Gross profit TTM US$443.4 million
Return on assets TTM 11.46%
Return on equity TTM 25.16%
Profit margin 21.61%
Book value 7.518
Market capitalisation US$642.4 million

TTM: trailing 12 months

Sinovac Biotech Ltd share dividends

We're not expecting Sinovac Biotech Ltd to pay a dividend over the next 12 months.

Sinovac Biotech Ltd share price volatility

Over the last 12 months, Sinovac Biotech Ltd's shares have ranged in value from as little as US$6.47 up to US$6.47. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sinovac Biotech Ltd's is 0.0649. This would suggest that Sinovac Biotech Ltd's shares are less volatile than average (for this exchange).

Sinovac Biotech Ltd overview

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site